Profile data is unavailable for this security.
About the company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
- Revenue in USD (TTM)1.97bn
- Net income in USD92.93m
- Incorporated1996
- Employees5.90k
- LocationQiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
- Phone+31 773556600
- Fax+31 773208409
- Websitehttps://www.qiagen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent Inc | 0.00 | -224.29m | 5.95bn | 127.00 | -- | 5.77 | -- | -- | -3.48 | -3.48 | 0.00 | 15.81 | 0.00 | -- | -- | 0.00 | -27.79 | -- | -29.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Blueprint Medicines Corp | 434.41m | -128.05m | 6.02bn | 638.00 | -- | 19.21 | -- | 13.86 | -2.11 | -2.11 | 6.92 | 4.93 | 0.3769 | 0.8954 | 8.11 | 663,227.50 | -11.11 | -29.92 | -13.84 | -34.06 | 97.01 | -- | -29.48 | -116.65 | 3.27 | -10.80 | 0.5525 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Madrigal Pharmaceuticals Inc | 76.81m | -518.67m | 6.92bn | 376.00 | -- | 8.90 | -- | 90.04 | -25.07 | -25.07 | 3.71 | 35.64 | 0.1172 | -- | -- | 204,289.90 | -79.11 | -62.09 | -100.35 | -74.81 | 96.37 | -- | -675.24 | -- | 5.93 | -- | 0.1309 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Legend Biotech Corp (ADR) | 520.18m | -348.13m | 7.40bn | 2.40k | -- | 6.60 | -- | 14.22 | -1.91 | -1.91 | 2.85 | 6.08 | 0.291 | 9.29 | 1,434.99 | 288,990.60 | -19.47 | -37.71 | -22.25 | -47.19 | 62.88 | -- | -66.92 | -286.51 | 4.90 | -- | 0.237 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Tempus AI Inc | 640.44m | -800.71m | 9.16bn | 2.30k | -- | 168.11 | -- | 14.30 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Qiagen NV | 1.97bn | 92.93m | 9.42bn | 5.90k | 103.16 | 2.65 | 31.18 | 4.79 | 0.408 | 0.408 | 8.80 | 15.88 | 0.3229 | 2.03 | 5.71 | 329,508.00 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 9.60bn | 490.00 | -- | 6.11 | -- | 12,938.38 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.61bn | 20.00k | 23.46 | 2.54 | 12.51 | 2.37 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.75bn | 6.50k | -- | 3.04 | 5,350.26 | 3.62 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.90bn | 1.31k | 22.08 | 4.35 | 20.01 | 4.75 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.14bn | 5.90k | 28.55 | 11.47 | 25.70 | 4.89 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.59bn | 1.31k | 91.16 | 8.67 | 65.98 | 6.46 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 10.71bn | 254.00 | -- | 3.13 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 10.92bn | 3.10k | 73.09 | 5.11 | 41.67 | 9.32 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.48bn | 1.70k | 33.02 | 4.59 | 30.33 | 5.57 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Data as of Nov 22 2024. Currency figures normalised to Qiagen NV's reporting currency: US Dollar USD
35.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 23.12m | 10.42% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 13.69m | 6.17% |
| Wellington Management International Ltd.as of 30 Sep 2024 | 6.52m | 2.94% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 6.08m | 2.74% |
| Amundi Asset Management US, Inc.as of 30 Sep 2024 | 5.66m | 2.55% |
| MFS International (UK) Ltd.as of 30 Sep 2024 | 5.11m | 2.31% |
| MFS International Singapore Pte Ltd.as of 30 Sep 2024 | 4.72m | 2.13% |
| Nuance Investments LLCas of 30 Sep 2024 | 4.49m | 2.03% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 4.19m | 1.89% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.16m | 1.87% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
